2DR Debate: Should the Majority of People Living with HIV Be on a 2DR Regimen?

About this Program

Currently, most of the treatment guidelines are dominated by three-drug combination ART with two drug combinations starting to be recognized as a preferred therapy in naïve patients.

However, two drug strategies including those of newer compounds and formulations (single pills/injections) are beginning to be used extensively in people who switch because of simplification, side effects, or potential drug interactions, in some patients with prior failure and resistance and even as an option in the rapid start strategy.

Multiple clinical studies have shown that HIV treatment with a two-drug (2DR) combination is non-inferior to the three-drug combination in start and switch studies e.g the Gemini-1, Gemini-2 in Naïve; DTG/3TC was non-inferior to DTG + tenofovir/emtricitabine (1). Tango and Salsa trials proved that switching to or maintaining (DTG/3TC) was virologically non-inferior to maintaining a 3- or 4-drug regimen including tenofovir alafenamide (TAF) through 144 weeks (2,3). Sword (DTG/RPV) showed efficacy and safety data for switching to DTG/RPV for 1st line and 2nd line ART therapies (4).

Making the medical community more aware of this 2DR concept and showing the opportunities in various treatment situations but also the limitations, it’s important to discuss the pros and cons of this new strategy.

This debate led to an improved understanding of the two-drug concept and will enable the prescribers to make well-considered decisions on selecting the most optimal treatment option for their patients.

The interactive quiz element was used to discuss the clinical data and will allow the participants to improve their knowledge.

Program Director

Anton Pozniak, MD, FRCP

Chelsea and Westminster Hospital, United Kingdom

General Information

COVID-19 Update

Responding to the changing COVID-19 situation, the "2DR Debate: Should the Majority People Living with HIV Be on a 2DR Regimen?" will be held as a hybrid meeting. The meeting will be held in Glasgow, United Kingdom, and also offers the opportunity to participate virtually.

By merging in-person communication and virtual elements, the hybrid meeting format is an optimal solution in light of the current circumstances. The Conference Organizers will continue to observe the ongoing COVID-19 pandemic and will take necessary steps to ensure that the meeting will be held in compliance with relevant regulations, prioritizing the health and safety of our participants.

We are available to answer any questions or concerns that you may have about your participation in the 2DR Debate: Should the Majority of People Living with HIV Be on a 2DR Regimen? For more information, please contact us at federica.ressa@amededu.com.

To stay updated on developments about this meeting, make sure that you are signed up for our newsletter.

Who Should Attend?

Clinicians, physicians, nurses, and healthcare professionals.

Learning Objectives

After participating in this event, participants will be able to:

- Outline the options for using a 2DR regimen;

- Reflect on the different clinical parameters needed to take into consideration when selecting a 2DR regimen for their patients; and

- Translate the clinical research data into clear practice guidelines for clinical management of People Living with HIV.

Practical Information

Venue

The 2DR Debate took place at Hilton Glasgow (1 William St. Glasgow G3 8HT, United Kingdom).

Travel

No travel is included in the registration.

Accommodation

Accommodation is not included in the registration.

Badges

All participants are requested to wear the badge at all times during the conference to ensure admission to the meeting.

Certificate of Attendance

A digital certificate of attendance will be sent to participants after successfully completing the program and post-meeting survey.

Language

The official language of the symposium is English. Translation will/will not be provided.

Enduring Materials

After receiving consent from the presenters, the presentations will be posted on Academic Medical Education following the event.

Disclaimer

This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.

Liability and Insurance

By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.

Photographs, Audio, and Video Recording

Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.

Code of Conduct

All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.